Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 284 results
Press release cover image

Aug 7, 2026

Greenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular Dystrophy

Award supports an iPSC and AI-driven drug discovery program targeting the leading cause of death in DMD patientsPALO ALTO, Calif.--(BUSINESS WIRE)--#BioPharma--Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, today announced that it has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH). The award funds a research program to discover novel d
A minimalist representation of a drug molecule in a dark color scheme.

Aug 6, 2026

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Clarivate has announced the enhancement of its agentic AI capabilities within the Cortellis portfolio, aimed at streamlining drug development processes for life sciences organizations.This expansion allows research and development teams to leverage AI to accelerate discovery, improve safety assessments, and make informed decisions throughout the drug development lifecycle. By integrating AI into existing workflows, researchers can minimize manual tasks and concentrate on strategic scientific dec
Press release cover image

Aug 6, 2026

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proofPISCATAWAY, N.J. and SAN FRANCISCO, Aug. 5, 2026 /PRNewswire/ -- Artificial intelligence can now generate thousands of potential drug molecules in the time it once took to design one, dramatically expanding what scientists can imagine. Yet deciding which designs merit further investment still depends on experimental p
Press release cover image

Aug 6, 2026

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

NEW YORK--(BUSINESS WIRE)--#AgenticAI--Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization. Building on a long-standing partnership with BMS where they routinely utilize Schrödinger’s industry-leading computational platform, the new agreement significantly expands the application of Schrödinger’s platform, empowering BMS scientists to explore more scientifi
Press release cover image

Aug 4, 2026

Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota’s Department of Chemistry
Flat design of a bispecific antibody-drug conjugate

Aug 4, 2026

Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact

Pathos AI has expanded its therapeutic pipeline through a significant acquisition from Alphamab Oncology and a collaboration with AstraZeneca, reflecting its commitment to leveraging AI in drug development.The New York-based biotechnology firm has agreed to pay $125 million for the bispecific antibody-drug conjugate (ADC) JSKN016, which targets TROP2 and HER3. This ADC is already in phase 3 trials, demonstrating its advanced stage in development. Pathos AI utilized its AI-driven decision platfor
A minimalist representation of a peptide structure and AI model in flat design.

Aug 3, 2026

Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets

Receptor.AI and Sethera are collaborating to develop an innovative closed-loop drug discovery workflow aimed at addressing challenging therapeutic targets.The partnership will leverage Sethera's advanced platform, which enables the creation and experimental screening of diverse polymacrocyclic peptide libraries. This approach allows for the generation of unique peptide architectures, moving beyond traditional design methods that rely on fixed structural motifs. Receptor.AI will complement this b
A flat illustration of a proxy drug molecule interacting with a target protein in a laboratory setting.

Jul 28, 2026

Insights from SLAS Europe 2026 - SelectScience interview

At the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), researchers are pioneering the integration of academic research and industrial applications in drug discovery. Their focus is on developing proximity-inducing drugs, which differ from traditional small molecules by modulating protein interactions rather than merely inhibiting protein functions.Proximity-inducing drugs, or proxy drugs, operate by binding to a target protein and recruiting another protein via mechanism
A minimalist illustration of a pill and bacteria in flat design.

Jul 27, 2026

Antares project launches: AI aims to accelerate search for new antibacterials

The Antares project, a collaborative initiative funded by the German Federal Ministry of Research, Technology and Space, aims to leverage artificial intelligence in the search for new antibiotics. This public-private partnership involves key players like the Fraunhofer ITMP, Helmholtz Centre for Infection Research, and Enamine Deutschland, focusing on developing effective treatments for drug-resistant infections.The project employs AI models trained on publicly accessible datasets to streamline
A minimalist representation of a bispecific antibody targeting tumor antigens.

Jul 27, 2026

VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens

VERAXA Biotech has announced the advancement of its bispecific antibody drug conjugate (bsADC) program, VXA-222, following a successful milestone in collaboration with OmniAb. This innovative therapy targets two distinct tumor antigens simultaneously, utilizing an “AND-gate” mechanism.VXA-222 represents a significant step forward in cancer treatment, addressing solid tumors that currently have high unmet medical needs. The collaboration leverages OmniAb’s advanced antibody discovery technologies
A minimalist illustration of a molecule and a contract representing biotech growth.

Jul 24, 2026

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

MindWalk Holdings Corp. has reported significant financial growth, showcasing the tangible impact of its AI-driven drug discovery platform.In its recent fiscal report, MindWalk Holdings, a company specializing in AI applications for drug discovery, announced a 46% revenue increase, reaching C$15.6 million. This surge is coupled with a notable reduction in net losses, which fell by over 50% to C$13.9 million. The company also achieved a critical milestone by signing its first two recurring enterp
Minimalist illustration of an antibody structure

Jul 23, 2026

Creative Biolabs launches end-to-end AI-driven antibody solutions

Creative Biolabs has introduced a comprehensive AI-driven platform designed to revolutionize the antibody discovery process in biopharmaceuticals, significantly reducing timelines for early-stage development.This innovative framework integrates generative deep-learning models with high-throughput experimental workflows, addressing common structural challenges in drug development. Traditional antibody discovery often suffers from high attrition rates due to unfavorable biophysical properties and